4L9K

X-ray study of human serum albumin complexed with camptothecin

Summary for 4L9K

• Entry DOI: 10.2210/pdb4l9k/pdb
• Related: 4L8U 4L9Q 4LA0 4LB2 4LB9
• Descriptor: SERUM ALBUMIN, (2S)-2-hydroxy-2-[8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]butanoic acid (3 entities in total)
• Functional Keywords: plasma protein, cancer, oncology drug complex, transport protein
• Biological source: Homo sapiens (human)
• Cellular location: Secreted: P02768
• Total number of polymer chains: 2
• Total formula weight: 133875.17

Authors

Wang, Z.,Ho, J.X.,Ruble, J.,Rose, J.P.,Carter, D.C. (deposition date: 2013-06-18, release date: 2013-07-24, Last modification date: 2024-11-27)

Primary citation

Wang, Z.M.,Ho, J.X.,Ruble, J.R.,Rose, J.,Ruker, F.,Ellenburg, M.,Murphy, R.,Click, J.,Soistman, E.,Wilkerson, L.,Carter, D.C.
Structural studies of several clinically important oncology drugs in complex with human serum albumin.
Biochim.Biophys.Acta, 1830:5356-5374, 2013

PubMed Abstract: Serum albumin is a major pharmacokinetic effector of drugs. To gain further insight into albumin binding chemistry, the crystal structures of six oncology agents were determined in complex with human serum albumin at resolutions of 2.8 to 2.0Å: camptothecin, 9-amino-camptothecin, etoposide, teniposide, bicalutamide and idarubicin.

PubMed: 23838380
DOI: 10.1016/j.bbagen.2013.06.032

Experimental method

X-RAY DIFFRACTION (2.4 Å)